Abstract
There is compelling evidence from seven RCTs that a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy given after optimal cytoreductive surgery significantly improves survival for women with FIGO stage III epithelial ovarian cancer. On the basis of this data, the US-NCI issued a Clinical Announcement in January 2006 recommending that women and their physicians consider such combined IV/IP chemotherapy where appropriate. Despite ongoing educational efforts, IP/IV regimens have not become the standard of care in many hospitals. Ongoing clinical research seeks to reduce the toxicity associated with IP chemotherapy while retaining efficacy and integrating new biological approaches to treatment. Copyrigth
| Original language | Spanish |
|---|---|
| Pages (from-to) | 323-325 |
| Number of pages | 3 |
| Journal | Salud(i)Ciencia |
| Volume | 18 |
| Issue number | 4 |
| State | Published - Jun 2011 |
| Externally published | Yes |
Fingerprint
Keywords
- Chemotherapy
- Epithelial ovarian cancer
- Intraperitoneal chemotherapy
- Treatment
ASJC Scopus subject areas
- Medicine(all)
Cite this
La combinación de quimioterapia intravenosa e intraperitoneal mejora la supervivencia en el cáncer de ovario. / Minig, Lucas; Trimble, Edward.
In: Salud(i)Ciencia, Vol. 18, No. 4, 06.2011, p. 323-325.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - La combinación de quimioterapia intravenosa e intraperitoneal mejora la supervivencia en el cáncer de ovario
AU - Minig, Lucas
AU - Trimble, Edward
PY - 2011/6
Y1 - 2011/6
N2 - There is compelling evidence from seven RCTs that a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy given after optimal cytoreductive surgery significantly improves survival for women with FIGO stage III epithelial ovarian cancer. On the basis of this data, the US-NCI issued a Clinical Announcement in January 2006 recommending that women and their physicians consider such combined IV/IP chemotherapy where appropriate. Despite ongoing educational efforts, IP/IV regimens have not become the standard of care in many hospitals. Ongoing clinical research seeks to reduce the toxicity associated with IP chemotherapy while retaining efficacy and integrating new biological approaches to treatment. Copyrigth
AB - There is compelling evidence from seven RCTs that a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy given after optimal cytoreductive surgery significantly improves survival for women with FIGO stage III epithelial ovarian cancer. On the basis of this data, the US-NCI issued a Clinical Announcement in January 2006 recommending that women and their physicians consider such combined IV/IP chemotherapy where appropriate. Despite ongoing educational efforts, IP/IV regimens have not become the standard of care in many hospitals. Ongoing clinical research seeks to reduce the toxicity associated with IP chemotherapy while retaining efficacy and integrating new biological approaches to treatment. Copyrigth
KW - Chemotherapy
KW - Epithelial ovarian cancer
KW - Intraperitoneal chemotherapy
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84863832329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863832329&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:84863832329
VL - 18
SP - 323
EP - 325
JO - Salud (i) Ciencia
JF - Salud (i) Ciencia
SN - 1667-8982
IS - 4
ER -